Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Natera

Tracked across 3 events · 20 articles · First seen Apr 10, 2026 · Last active Aug 05, 2026

Sentiment
60
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Natera is collaborating with Diakonos Oncology Corporation to use its Signatera test in a clinical trial, potentially expanding its market and demonstrating the utility of its precision medicine platform.
May 29, 2026 · 6 articles
4 70
Business
Impact: Natera entered a strategic partnership with Aveta Biomics to support the AVTA 30-01 trial, which is expected to increase the use of its Signatera testing platform and potentially boost its revenue and market position. Its shares rose more than 3% in pre-market trading.
Jun 29, 2026 · 7 articles
4 40
Regulatory
Impact: Natera is the applicant and primary beneficiary, seeking PMDA approval to expand Signatera's use in Japan. The submission follows recent FDA and NCCN endorsements, reinforcing its leadership in MRD testing.
Aug 05, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Natera live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.